N. Ahmad, S. D. Ahuja, O. W. Akkerman, J. C. Alffenaar, L. F. Anderson et al., The Lancet, vol.392, issue.18, pp.31644-31645, 2018.

. Aidsinfo, Directly Observed Therapy (DOT) Definition [WWW Document, 2018.

. Aidsinfo,

, SIRTURO® (bedaquiline) Development and Launch

K. Andries, P. Verhasselt, J. Guillemont, H. W. Göhlmann, J. Neefs et al., A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis, Science, vol.307, pp.223-227, 2005.

A. E. Attema, W. B. Brouwer, and K. Claxton, Discounting in Economic Evaluations, Pharmacoeconomics, vol.36, pp.745-758, 2018.

P. Aubry and B. Gaüzère, Tubeculose Actualites, 2018.

B. Magali, Procurement update: StopTB Partnership-Global Drug Dacility (GDF), 2018.

J. R. Beck and S. G. Pauker, The Markov process in medical prognosis, Med Decis Making, vol.3, pp.419-458, 1983.

A. Bhargava, M. Chatterjee, Y. Jain, B. Chatterjee, A. Kataria et al., Nutritional Status of Adult Patients with Pulmonary Tuberculosis in Rural Central India and Its Association with Mortality, PLoS One, vol.8, 2013.

S. E. Borisov, K. Dheda, M. Enwerem, R. Romero-leyet, L. D'ambrosio et al., Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR-and XDR-TB: a multicentre study, vol.49, 2017.

L. R. Codecasa, M. Toumi, A. D'ausilio, A. Aiello, F. Damele et al., Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy, Journal of Market Access & Health Policy, vol.5, p.1283105, 2017.

F. Conradie, A. H. Diacon, D. Everitt, C. Mendel, C. Van-niekerk et al., The NIX-TB trial of pretomanid, 2017.

, Country Updates, 2018.

. Deloitte, Big pharma's market access mission, 2018.

. Deloitte,

A. H. Diacon, A. Pym, M. P. Grobusch, J. M. De-los-rios, E. Gotuzzo et al., Multidrug-resistant tuberculosis and culture conversion with bedaquiline, N. Engl. J. Med, vol.371, pp.723-732, 2014.

M. F. Drummond, M. J. Schulpher, K. Claxton, G. L. Stoddart, and G. W. Torrance, Methods for the Economics Evaluation of Health Care Programmes, 2015.

I. Durand-zaleski, Études coût-efficacité: idées fausses et éléments de méthode. Archives of Cardiovascular Diseases Supplements, Rapport coût-effi cacité des traitements médicamenteux et interventionnels dans la fibrillation atriale 8, EndTB Interim Analysis. Global Snapshot, issue.16, pp.30329-30338, 2016.

. Globalhealthpr, , 2018.

L. Guglielmetti, M. Jaspard, D. Le-dû, M. Lachâtre, D. Marigot-outtandy et al., Long-term outcome and safety of prolonged bedaquiline treatment for multidrugresistant tuberculosis, Eur. Respir. J, vol.49, 2017.
DOI : 10.1183/13993003.01799-2016

URL : https://hal.archives-ouvertes.fr/hal-01489714

I. Gupta and M. Bhatia, India : International Health Care System Profiles [WWW Document]. The Common wealth fund, vol.18, 2016.

N. Homedes, The Disability-Adjusted Life Year (DALY) Definition, Measurement and Potential Use, 1996.

. Htasialink, , vol.18

H. Hu, J. Chen, K. D. Sato, Y. Zhou, H. Jiang et al., Factors that associated with TB patient admission rate and TB inpatient service cost: a cross-sectional study in China, Infect Dis Poverty, vol.5, 2016.
DOI : 10.1186/s40249-016-0097-x

URL : https://idpjournal.biomedcentral.com/track/pdf/10.1186/s40249-016-0097-x

A. Ionescu, A. Mpobela-agnarson, C. Kambili, L. Metz, J. Kfoury et al., Bedaquiline-versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis, Expert Review of Pharmacoeconomics & Outcomes Research, vol.18, pp.677-689, 2018.
DOI : 10.1080/14737167.2018.1507821

URL : https://www.tandfonline.com/doi/pdf/10.1080/14737167.2018.1507821?needAccess=true

. Janssen, , 2016.

. Johnson&johnson, SIRTURO® (bedaquiline)| Mechanism of Action [WWW Document, SIRTURO® Official website, 2018.

. Johnson&johnson, Janssen joins partnership in China to provide access to SIRTURO® (bedaquiline) for the treatment of multidrug-resistant tuberculosis (MDR-TB) | Xian Janssen Pharmaceutical Ltd, 2018.

. Johnson&johnson, Janssen remporte le Prix Galien International 2016 pour la bédaquiline, 2016.

J. France,

E. A. Kendall, G. Brigden, C. Lienhardt, and D. W. Dowdy, Would pan-tuberculosis treatment regimens be cost-effective?, The Lancet Respiratory Medicine, vol.6, pp.30197-30205, 2018.
DOI : 10.1016/s2213-2600(18)30197-8

G. Kobelt, Health Economics: An introduction to Economic Evaluation, The Office of Health Economics (OHE), 2002.

A. Koul, L. Vranckx, N. Dendouga, W. Balemans, I. Van-den-wyngaert et al., Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis, J. Biol. Chem, vol.283, pp.25273-25280, 2008.

A. Kumar, K. Juluru, P. K. Thimmaraju, J. Reddy, and A. Patil, Pharmaceutical market access in emerging markets: concepts, components, and future, J Mark Access Health Policy, vol.2, 2014.
DOI : 10.3402/jmahp.v2.25302

URL : https://doi.org/10.3402/jmahp.v2.25302

C. Le-pen and P. Levy, L'évaluation médico-économique-Concepts et méthodes, Editions Le Grand Metier, 2018.

A. Lebrun, J. Lee, M. W. Carroll, H. Choi, S. Min et al., Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis, L'Institut Pasteur veut ressusciter le BCG avec des souches centenaires. 03/04/2018. Lee, vol.367, pp.1508-1518, 2012.

C. Lienhardt, L. González-angulo, D. Falzon, E. Jaramillo, and K. Weyer, The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance, 2016.

P. L. Lin and J. L. Flynn, Understanding latent tuberculosis: a moving target, J. Immunol, vol.185, pp.15-22, 2010.
DOI : 10.4049/jimmunol.0903856

URL : http://www.jimmunol.org/content/jimmunol/185/1/15.full.pdf

, Live China population, 2018.

. Countymeters, , vol.18

Q. Long, H. Smith, T. Zhang, S. Tang, and P. Garner, Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review, BMC Public Health, vol.11, 2011.

X. Lu, C. Smare, C. Kambili, A. C. El-khoury, and L. J. Wolfson, Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries, BMC Health Services Research, vol.17, 2017.

, South Africa Becomes First Country to Include New, More Effective DRTB Drug in Standard Treatment [WWW Document]. Doctors Without Borders-USA, 2018.

, Ministry of Health & Family Welfare, National Health Policy, 2014.

J. B. Mullerpattan, Z. Z. Udwadia, R. A. Banka, S. R. Ganatra, and Z. F. Udwadia, Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India, Indian Journal of Tuberculosis, 2018.

B. M. Muniyandi, V. Rao, J. Bhat, R. Yadav, and R. Sharma, Household Catastrophic Health Expenditure Due to Tuberculosis : Analysis from Particularly Vulnerable Tribal Group, 2015.

J. P. Nair, A. U. Athavale, V. S. Khatri, and T. Saxena, Financial Implications in Management of Multidrug Resistant Tuberculosis in India, International Journal of Science and Research (IJSR), vol.6, pp.535-539, 2017.

I. D. Olaru, J. Heyckendorf, S. Andres, B. Kalsdorf, and C. Lange, Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis, Eur. Respir. J, vol.49, 2017.

O. Olayanju, J. Limberis, A. Esmail, S. Oelofse, P. Gina et al., Long-term bedaquiline-related treatment outcomes in patients with extensively drugresistant tuberculosis from South Africa, European Respiratory Journal, vol.51, 2018.

, OMS, 2018.

O. and 2. , OMS lance un appel à agir d'urgence pour mettre fin à la tuberculose

, OMS, 2018.

, Rapid Communication: Key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB) 9, OMS, 2018.

, OMS, 2017.

, Seuils de rentabilité: avantages et inconvénients, OMS, 2016.

, Cost-effectiveness thresholds: pros and cons, OMS, 2016.

O. Shorter and M. Regimen,

O. , Les différents types de résistance aux médicaments antituberculeux

O. and N. D. , Health Profile of India [WWW Document

O. and N. D. , Health profile of China [WWW Document

O. and N. D. , World Health Organization: Tuberculosis in China a Disease of Poverty

, WHO treatment guidelines for drug-resistant tuberculosis: 2016 update, OMS, 2016.

O. and O. , How Pharmaceutical systems are organized in Asia and the Pacific, 2018.

, Pour le ministre indien de la santé, « l'heure est venue d'en finir avec la tuberculose, OPINIONS, 2018.

N. Padayatchi, M. Gopal, R. Naidoo, L. Werner, K. Naidoo et al., Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study, Journal of Antimicrobial Chemotherapy, vol.69, pp.3103-3107, 2014.

Y. Pan, S. Chen, M. Chen, P. Zhang, Q. Long et al., Disparity in reimbursement for tuberculosis care among different health insurance schemes: evidence from three counties in central China, Infect Dis Poverty, vol.5, 2016.

H. Park, H. Ku, H. Sohn, H. Seo, Y. Lee et al., Costeffectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea, Clinical Therapeutics, vol.38, pp.655-667, 2016.

T. Prasanna, K. Jeyashree, P. Chinnakali, Y. Bahurupi, K. Vasudevan et al., Catastrophic costs of tuberculosis care: a mixed methods study from Puducherry, India. Glob Health Action, vol.11, 2018.

A. S. Pym, A. H. Diacon, S. Tang, F. Conradie, M. Danilovits et al., Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis, Eur. Respir. J, vol.47, pp.564-574, 2016.

R. Rajeswari, . Balasubramanian, . Muniyandi, . Geetharamani, . Thresa et al., Socio-economic impact of tuberculosis on patients and family in India, The International Journal of Tuberculosis and Lung Disease, issue.10, pp.869-77, 1999.

R. Swasthya-bima and . Yojana,

R. Sirturo, Central TB Division, Ministry of Health and Family Welfare, RNTCP, 2014.

. Rxlist, Sirturo (Bedaquiline Tablets) [WWW Document, 2017.

J. Sachs, Macroeconomics and health: investing in health for economic development ; report of the Commission on Macroeconomics and Health. OMS, Geneva. Sandesh Adhikari, 2017. DALY (Disability Adjusted Life Years), 2001.

K. Schnippel, N. Ndjeka, G. Maartens, G. Meintjes, I. Master et al., Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study, The Lancet Respiratory Medicine, vol.6, issue.18, pp.30235-30237, 2018.

A. Skrahina, H. Hurevich, D. Falzon, L. Zhilevich, V. Rusovich et al., Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience, Int J Mycobacteriol, vol.5, issue.1, pp.62-63, 2016.

T. B. Stop and . Partnership, Global Drug Facility (GDF) [WWW Document, vol.18, 2018.

T. B. Stop and . Partnership, The Bedaquiline Donation Program [WWW Document, 2018.

S. Tang, L. Wang, H. Wang, and D. P. Chin, Access to and affordability of healthcare for TB patients in China: issues and challenges, TB Facts | TB, tests, drugs, vol.5, 2016.

, Eligibility List, p.408030000000, 2018.

, South Africa announces lower price for TB drug bedaquiline [WWW Document]. The Union, 2018.

F. Varaine and M. L. Rich, Caractéristiques de Mycobacterium tuberculosis-Tuberculosis

A. Vassal, Cost-effectiveness of introducing Bedaquiline in MDR-TB regimens-a exploratory analysis, 2013.

N. Vergne, L'histoire de la tuberculose et de ses traitements, 1994.

L. Wang, R. Li, C. Xu, H. Zhang, Y. Ruan et al., The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership, PLOS ONE, vol.12, 2017.

X. Wang, New drug to be provided free to Chinese TB patients, 2018.

W. Bennett and J. , What is an Antibiotic?, Antibiotics: Current Innovations and Future Trends, 2015.

C. Wight, The true meaning of market access?, 2012.

. Pmlive, , vol.18

L. J. Wolfson, J. Gibbert, D. Wirth, and R. Diel, Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany, European Respiratory Journal, vol.46, pp.1826-1829, 2015.

L. J. Wolfson, A. Walker, R. Hettle, X. Lu, C. Kambili et al., Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK, PLOS ONE, vol.10, 2015.

, Drug-Resistant Infections: A Threat to Our Economic Future, 2016.

K. Xu, D. B. Evans, K. Kawabata, R. Zeramdini, J. Klavus et al., Household catastrophic health expenditure: a multicountry analysis, The Lancet, vol.362, pp.13861-13866, 2003.

Y. Zhao, T. Fox, K. Manning, A. Stewart, N. Tiffin et al., Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study, Clin. Infect. Dis, 2018.

C. Zhou, Q. Long, J. Chen, L. Xiang, Q. Li et al., Factors that determine catastrophic expenditure for tuberculosis care: a patient survey in China, Infectious Diseases of Poverty, vol.5, 2016.

A. I. Zumla, S. H. Gillespie, M. Hoelscher, P. P. Philips, S. T. Cole et al., , 2014.